Module 2 Summaries (2.5, 2.6, 2.7): Anatomy of the Project
Module 2 Summaries of the Common Technical Document (CTD) serve as the critical bridge between the detailed technical data of a drug development program and the high-level regulatory review process. Specifically, Sections 2.5 (Clinical Overview), 2.6 (Nonclinical Overview and Summaries), and 2.7 (Clinical Summaries) are concise yet comprehensive documents that synthesize the vast amount of clinical and nonclinical information presented elsewhere in the submission.
Each of these summaries plays a distinct and vital role:
Section 2.5 – Clinical Overview: This document provides a narrative-style overview that discusses the clinical rationale for the drug, its development history, benefit-risk assessment, and therapeutic positioning. It ties together efficacy, safety, and pharmacologic findings, offering regulatory reviewers a clear narrative to frame their evaluation.
Section 2.6 – Nonclinical Overview and Summaries: This includes both an integrated overview (2.6.1) and structured summaries (2.6.2–2.6.7) covering pharmacology, pharmacokinetics, and toxicology. These components present nonclinical findings in a way that highlights relevance to human safety and guides the interpretation of animal data in context of clinical use.
Section 2.7 – Clinical Summaries: Detailed but still focused, these summaries (2.7.1–2.7.6) systematically organize clinical data around pharmacokinetics, pharmacodynamics, efficacy, and safety findings. Unlike the narrative Clinical Overview, Clinical Summaries are highly structured and data-driven, often drawing heavily from statistical analyses presented in the full clinical study reports.
Preparing these Module 2 Summaries requires a balance of scientific depth, strategic communication, and regulatory precision. Writers must distill thousands of pages of data into clear, concise, and persuasive arguments that anticipate regulatory concerns and facilitate a smooth review.
At ScienceDocs, our regulatory writing team specializes in developing these summaries with efficiency and expertise. We work closely with clinical, nonclinical, statistical, and regulatory teams to ensure consistency across the submission and full alignment with ICH M4 guidelines. We also bring strategic insight into how best to present data narratives to highlight a product’s strengths while transparently addressing risks.
Whether for initial INDs, NDAs, or global submissions, we ensure that our clients’ Module 2 summaries tell a compelling, scientifically sound story that prepares the ground for regulatory success.
We would be delighted to assist you with any of your regulatory writing needs. Feel free to contact us and one of our Project Managers will be right back to you to set up a meeting.